Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia

Canadian Journal of Psychiatry

Volumn 50, Issue 11, 2005, Pages 703-714

  Margolese, Howard C ^a,b,e   Chouinard, Guy ^b,c,d   Kolivakis, Theodore T ^a   Beauclair, Linda ^a,b,e   Miller, Robert ^f   Annable, Lawrence ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

^e Allan Memorial Institute   (Canada)

^f UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Antipsychotics; Extrapyramidal symptoms; Psychosis; Schizophrenia; Tardive dyskinesia

Indexed keywords

ALPHA TOCOPHEROL; AMINO ACID; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; DONEPEZIL; FLUPENTIXOL; GABAPENTIN; HALOPERIDOL; MELATONIN; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PYRIDOXINE; QUETIAPINE; RISPERIDONE; TETRABENAZINE; ZIPRASIDONE; ZUCLOPENTHIXOL;

ANXIETY DISORDER; BIPOLAR DISORDER; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; HUMAN; MEDICAL LITERATURE; MORBIDITY; MOTOR DYSFUNCTION; PSYCHOSIS; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; TARDIVE DYSKINESIA; TIME SERIES ANALYSIS;

EID: 31744443145     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674370505001110     Document Type: Review

References (139)

1. Jeste DV, Lacro JP, Bailey A, Rockwell E, Harris MJ, Caligiuri MP. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc 1999;47:716-9.
2. Jeste DV, Okamoto A, Napolitano J, Kane JM, Martinez RA. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry 2000;157:1150-5.
3. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, and others. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40.
4. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997;58:538-46.
5. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry 1995;166:712-26.
6. Lemmens P, Brecher M, Van Baelen B. A combined analysis of double-blind studies with risperidone vs placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms. Acta Psychiatr Scand 1999;99:160-70.
7. Simpson GM, Lindenmayer JP. Extrapyramidal symptoms in patients treated with risperidone. J Clin Psychopharmacol 1997;17:194-201.
8. Moller HJ, Gagiano CA, Addington DE, Von Knorring L, Torres-Plank JF, Gaussares C. Long-term treatment of chronic schizophrenia with risperidone: an open-label, multicenter study of 386 patients. Int Clin Psychopharmacol 1998;13:99-106.
9. Anand VS, Dewan MJ. Withdrawal-emergent dyskinesia in a patient on risperidone undergoing dosage reduction. Ann Clin Psychiatry 1996;8:179-82.
10. Brown ES. Extrapyramidal side effects with low-dose risperidone. Can J Psychiatry 1997;42:325-6.
11. Feeney DJ, Klykylo W. Risperidone and tardive dyskinesia. J Am Acad Child Adolesc Psychiatry 1996;35:1421-2.
12. Saran BM. Risperidone-induced tardive dyskinesia. J Clin Psychiatry 1998;59:29-30.
13. Tollefson GD, Beasley CM Jr, Tamura RN, Tran PV, Potvin JH. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 1997;154:1248-54.
14. Beasley CM, Dellva MA, Tamura RN, Morgenstern H, Glazer WM, Ferguson K, and others. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 1999;174:23-30.
15. Jeste DV, Glazer WM, Morgenstern H, Pultz JA, Yeung PP. Rarity of tardive dyskinesia with quetiapine treatment of psychotic disorders in the elderly. Scientific Book of Abstracts, p. 142. The 38th Annual Meeting of the American College of Neuropsychopharmacology; 1999 Dec 12-16; 1999.
16. Glazer WM. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry 2000;61(Suppl 3):16-21.
17. Chouinard G, Lasser R, Bossie C, Zhu Y, Gharabawi G. Does a long-acting atypical antipsychotic offer low risk of tardive dyskinesia in patients with schizophrenia? Schizophr Res 60(1Suppl);277:2003.
18. Spivak M, Smart M. Tardive dyskinesia from low-dose risperidone. Can J Psychiatry 2000;45:202.
19. Sherr JD, Thaker G. Progression of abnormal involuntary movements during risperidone treatment. J Clin Psychiatry 1998;59:478-9.
20. Snoddgrass PL, Labbate LA. Tardive dyskinesia from risperidone and olanzapine in an alcoholic man. Can J Psychiatry 1999;44:921.
21. Hong KS, Cheong SS, Woo JM, Kim E. Risperidone-induced tardive dyskinesia. Am J Psychiatry 1999;156:1290.
22. Carroll NB, Boehm KE, Strickland RT. Chorea and tardive dyskinesia in a patient taking risperidone. J Clin Psychiatry 1999;60:485-7.
23. Campbell M. Risperidone-induced tardive dyskinesia in first-episode psychotic patients. J Clin Psychopharmacol 1999;19:276-7.
24. Haberfellner EM. Tardive dyskinesia during treatment with risperidone. Pharmacopsychiatry 1997;30:271.
25. Vieta E, Herraiz M, Parramon G, Goikolea JM, Fernandez A, Benabarre A. Risperidone in the treatment of mania: efficacy and safety results from a large, multicentre, open study in Spain. J Affect Disord 2002;72:15-9.
26. Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry 1999;60:107-15.
27. Buitelaar JK, van der Gaag RJ, Cohen-Kettenis P, Melman CT. A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry 2001;62:239-48.
28. Chouinard G, Annable L, Ross-Chouinard A, Mercier P. A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases. J Clin Psychopharmacol 1988;8:21S-26S.
29. Casey DE. Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophr Res 1991;4:109-20.
30. Berman I, Merson A, Sison C, Allan E, Schaefer C, Loberboym M, and others. Regional cerebral blood flow changes associated with risperidone treatment in elderly schizophrenia patients: a pilot study. Psychopharmacol Bull 1996;32:95-100.
31. Davidson M, Harvey PD, Vervarcke J, Gagiano CA, De Hooge JD, Bray G, and others. A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group. Int J Geriatr Psychiatry 2000;15:506-14.
32. Goldberg RJ, Goldberg J. Risperidone for dementia-related disturbed behavior in nursing home residents: a clinical experience. Int Psychogeriatr 1997;9:65-8.
33. Madhusoodanan S, Brecher M, Brenner R, Kasckow J, Kunik M, Negron AE, and others. Risperidone in the treatment of elderly patients with psychotic disorders. Am J Geriatr Psychiatry 1999;7:132-8.
34. Zarate CA Jr, Baldessarini RJ, Siegel AJ, Nakamura A, McDonald J, Muir-Hutchinson LA, and others. Risperidone in the elderly: a pharmacoepidemiologic study. J Clin Psychiatry 1997;58:311-7.
35. Chouinard G, Margolese HC. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res 2005;76:247-65.
36. Beasley CM Jr, Hamilton SH, Crawford AM, Dellva MA, Tollefson GD, Tran PV, and others. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997;7:125-37.
37. Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, and others. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-65.
38. Herran A, Vazquez-Barquero JL. Tardive dyskinesia associated with olanzapine. Ann Intern Med 1999;131:72.
39. Ananth J, Kenan J. Tardive dyskinesia associated with olanzapine monotherapy. J Clin Psychiatry 1999;60:870.
40. Benazzi F. Rapid onset of tardive dyskinesia in Huntington disease with olanzapine. J Clin Psychopharmacol 2002;22:438-9.
41. Bella VL, Piccoli F. Olanzepine-induced tardive dyskinesia. Br J Psychiatry 2003;182:81-2.
42. Chouinard G. New nomenclature for drug-induced movement disorders including tardive dyskinesia. J Clin Psychiatry 2004;65(Suppl 9):9-15.
43. Arvanitis LA, Miller BG. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997;42:233-46.
44. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 1997;54:549-57.
45. Ghelber D, Belmaker RH. Tardive dyskinesia with quetiapine. Am J Psychiatry 1999;156:796-7.
46. Ghaemi SN, Ko JY. Quetiapine-related tardive dyskinesia. Am J Psychiatry 2001;158:1737.
47. Sharma V. Treatment-emergent tardive dyskinesia with quetiapine in mood disorders. J Clin Psychopharmacol 2003;23:415-7.
48. Carnahan RM, Lund BC, Perry PJ. Ziprasidone, a new atypical antipsychotic drug. Pharmacotherapy 2001;21:717-30.
49. Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 1999;20:491-505.
50. Rosenquist KJ, Walker SS, Ghaemi SN. Tardive dyskinesia and ziprasidone. Am J Psychiatry 2002;159:1436.
51. Keck ME, Muller MB, Binder EB, Sonntag A, Holsboer F. Ziprasidone-related tardive dyskinesia. Am J Psychiatry 2004;161:175-6.
52. Casey DE. Effects of clozapine therapy in schizophrenic individuals at risk for tardive dyskinesia. J Clin Psychiatry 1998;59(Suppl3):31-7.
53. de Leon J, Moral L, Camunas C. Clozapine and jaw dyskinesia: a case report. J Clin Psychiatry 1991;52:494-5.
54. Dave M. Clozapine-related tardive dyskinesia. Biol Psychiatry 1994;35:886-7.
55. Kane JM, Woerner MG, Pollack S, Safferman AZ, Lieberman JA. Does clozapine cause tardive dyskinesia? J Clin Psychiatry 1993;54:327-30.
56. Miller dD. Clozapine and tardive dyskinesia. Am J Psychiatry 2003;160:588.
57. Kumet R, Freeman MP. Clozapine and tardive dyskinesia. J Clin Psychiatry 2002;63:167-8.
58. Doepp, S. and Buddeberg, C. Extrapyramidal symptoms following clozapine therapy. Nervenartz 1975;46:589-90.
59. Ganguli R. Rationale and strategies for switching antipsychotics. Am J Health Syst Pharm 2002;59:S22-S26.
60. Burns T, Chabannes JP, Demyttenaere K. Switching antipsychotic medications: general recommendations and switching to amisulpride. Curr Med Res Opin 2002;18:201-8.
61. Cutler AJ, Goldstein JM, Tumas JA. Dosing and switching strategies for quetiapine fumarate. Clin Ther 2002;24:209-22.
62. Kinon BJ, Basson BR, Gilmore JA, Malcolm S, Stauffer VL. Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. J Clin Psychiatry 2000;61:833-40.
63. Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacol 1995;15:36S-44S.
64. Emsley R, Turner HJ, Schronen J, Botha K, Smit R, Oosthuizen PP. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psychiatry 2004;65:696-701.
65. Farah A. Reduction of tardive dyskinesia with quetiapine. Schizophr Res 2001;47:309-10.
66. Meltzer HY, Bastani B, Ramirez L, Matsubara S. Clozapine: new research on efficacy and mechanism of action. Eur Arch Psychiatry Neurol Sci 1989;238:332-9.
67. Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry 1982;39:473-81.
68. Chouinard G, Annable L, Ross-Chouinard A, Nestoros JN. Factors related to tardive dyskinesia. Am J Psychiatry 1979;136:79-82.
69. Chouinard G, Annable L, Mercier P, Turnier L. Long-term effects of L-dopa and procyclidine on neuroleptic-induced extrapyramidal and schizophrenic symptoms. Psychopharmacol Bull 1987;23:221-6.
70. Tamminga CA, Thaker GK, Moran M, Kakigi T, Gao XM. Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry 1994;55(Suppl B):102-6.
71. Lieberman JA, Saltz BL, Johns CA, Pollack S, Borenstein M, Kane J. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991;158:503-10.
72. Bassitt DP, Louza Neto MR. Clozapine efficacy in tardive dyskinesia in schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 1998;248:209-11.
73. Carroll BJ, Curtis GC, Kokmen E. Paradoxical response to dopamine agonists in tardive dyskinesia. Am J Psychiatry 1977;134:785-9.
74. Chengappa KN, Shelton MD, Baker RW, Schooler NR, Baird J, Delaney J. The prevalence of akathisia in patients receiving stable doses of clozapine. J Clin Psychiatry 1994;55:142-5.
75. Dalack GW, Becks L, Meador-Woodruff JH. Tardive dyskinesia, clozapine, and treatment response. Prog Neuropsychopharmacol Biol Psychiatry 1998;22:567-73.
76. Gerbino L, Shopsin B, Collora M. Clozapine in the treatment of tardive dyskinesia: an interim report. In: Fann WE, Smith RC, Davis JM, Domino EF, editors. Tardive dyskinesia: research and treatment. New York: SP Medical and Scientific Books; 1980. p 475-89.
77. Gerlach J, Peacock L. Motor and mental side effects of clozapine. J Clin Psychiatry 1994;55(SupplB):107-9.
78. Gerlach J, Simmelsgaard H. Tardive dyskinesia during and following treatment with haloperidol, haloperidol + biperiden, thioridazine, and clozapine. Psychopharmacology (Berl) 1978;59:105-12.
79. Larach VW, Zamboni RT, Mancini HR, Mancini RR, Gallardo RT. New strategies for old problems: tardive dyskinesia (TD). Review and report on severe TD cases treated with clozapine, with 12, 8 and 5 years of video follow-up. Schizophr Res 1997;28:231-46.
80. Levkovitch Y, Kronenberg J, Kayser N, Zvyagelski M, Gaoni B, Gadoth N. Clozapine for tardive dyskinesia in adolescents. Brain Dev 1995;17:213-5.
81. Littrell K, Magill AM. The effect of clozapine on preexisting tardive dyskinesia. J Psychosoc Nurs Ment Health Serv 1993;31:14-8.
82. Meltzer HY, Luchins DJ. Effect of clozapine in severe tardive dyskinesia: a case report. J Clin Psychopharmacol 1984;4:286-7.
83. Modestin J, Stephan PL, Erni T, Umari T. Prevalence of extrapyramidal syndromes in psychiatric inpatients and the relationship of clozapine treatment to tardive dyskinesia. Schizophr Res 2000;42:223-30.
84. Naber D, Leppig M, Grohmann R, Hippius H. Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia - a retrospective study of 387 patients. Psychopharmacology (Berl) 1989;99(Suppl):S73-S76.
85. Nair C, Abraham G, de Leon J, Stanilla JK, Josiaspen RC, Simpson G. Dose-related effects of clozapine on tardive dyskinesia among "treatment-refractory" patients with schizophrenia. Biol Psychiatry 1996;39:529-30.
86. Peacock L, Solgaard T, Lublin H, Gerlach J. Clozapine versus typical antipsychotics. A retro- and prospective study of extrapyramidal side effects. Psychopharmacology (Berl) 1996;124:188-96.
87. Shopsin B, Klein H, Aaronsom M, Collora M. Clozapine, chlorpromazine, and placebo in newly hospitalized, acutely schizophrenic patients: a controlled, double-blind comparison. Arch Gen Psychiatry 1979;36:657-64.
88. Simpson GM, Lee JH, Shrivastava RK. Clozapine in tardive dyskinesia. Psychopharmacology (Berl) 1978;56:75-80.
89. Small JG, Milstein V, Marhenke JD, Hall DD, Kellams JJ. Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis. J Clin Psychiatry 1987;48:263-7.
90. Spivak B, Mester R, Abesgaus J, Wittenberg N, Adlersberg S, Gonen N, and others. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. J Clin Psychiatry 1997;58:318-22.
91. Cole JO, Gardos G, Deal T. Drug trials in persistent tardive dyskinesia. In: Fann WE, Smith RC, Davis JM, Domino EF, editors. Tardive dyskinesia: research and treatment. New York: SP Medical and Scientific Books; 1980. p 419-27.
92. Factor SA, Friedman JH. The emerging role of clozapine in the treatment of movement disorders. Mov Disord 1997;12:483-96
93. Miller R, Chouinard G. Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biol Psychiatry 1993;34:713-38.
94. Caroff SN, Campbell EC, Havey J, Sullivan KA, Mann SC, Gallop R. Treatment of tardive dyskinesia with donepezil: a pilot study. J Clin Psychiatry 2001;62:772-5.
95. Shamir E, Barak Y, Shalman I, Laudon M, Zisapel N, Tarrasch R, and others. Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Arch Gen Psychiatry 2001;58:1049-52.
96. Lohr JB, Cadet JL, Lohr MA, Jeste DV, Wyatt RJ. Alpha-tocopherol in tardive dyskinesia. Lancet 1987;1:913-4.
97. Soares KV, McGrath JJ. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2001;CD000209.
98. Adler LA, Rotrosen J, Edson R, Lavori P, Lohr J, Hitzemann R, and others. Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group. Arch Gen Psychiatry 1999;56:836-41.
99. Lerner V, Miodownik C, Kaptsan A, Cohen H, Matar M, Loewenthal U, and others. Vitamin B(6) in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry 2001;158:1511-4.
100. Richardson MA, Bevans ML, Read LL, Chao HM, Clelland JD, Suckow RF, and others. Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men. Am J Psychiatry 2003;160:1117-24.
101. Gerding LB, Labbate LA. Use of clonazepam in an elderly bipolar patient with tardive dyskinesia: a case report. Ann Clin Psychiatry 1999;11:87-9.
102. Chouinard G, Young SN, Annable L. Antimanic effect of clonazepam. Biol Psychiatry 1983;18:451-66.
103. Barnes TR, Kidger T. Clonazepam and tardive dyskinesia. Am J Psychiatry 1981;138:1127-8.
104. Bobruff A, Gardos G, Tarsy D, Rapkin RM, Cole JO, Moore P. Clonazepam and phenobarbital in tardive dyskinesia. Am J Psychiatry 1981;138:189-93.
105. Glazer WM, Hafez H. A comparison of masking effects of haloperidol versus molindone in tardive dyskinesia. Schizophr Res 1990;3:315-20.
106. Jeste DV, Wyatt RJ. In search of treatment for tardive dyskinesia: review of the literature. Schizophr Bull 1979;5:251-93.
107. Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry 1999;156:1279-81.
108. Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997;48:358-62.
109. Bruneau MA, Lesperance P, Chouinard S. Catastrophic reactions induced by tetrabenazine. Can J Psychiatry 2002;47:683.
110. Jeste DV, Wyatt RJ. Therapeutic strategies against tardive dyskinesia. Two decades of experience. Arch Gen Psychiatry 1982;39:803-16.
111. Klawans HL, Tanner CM, Barr A. The reversibility of "permanent" tardive dyskinesia. Clin Neuropharmacol 1984;7:153-9.
112. Gilbert PL, Harris MJ, McAdams LA, Jeste DV. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch Gen Psychiatry 1995;52:173-88.
113. van Harten PN, Hoek HW, Matroos GE, Koeter M, Kahn RS. Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curacao Extrapyramidal Syndromes Study III. Am J Psychiatry 1998;155:565-7.
114. Jeste DV, Potkin SG, Sinha S, Feder S, Wyatt RJ. Tardive dyskinesia-reversible and persistent. Arch Gen Psychiatry 1979;36:585-90.
115. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982;39:486-7.
116. Silver H, Aharon N, Schwartz M. Attention deficit-hyperactivity disorder may be a risk factor for treatment-emergent tardive dyskinesia induced by risperidone. J Clin Psychopharmacol 2000;20:112-4.
117. Addington DE, Jones B, Bloom D, Chouinard G, Remington G, Albright P. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clin Ther 1993;15:917-26.
118. Woerner MG, Sheitman BB, Lieberman JA, Kane JM. Tardive dyskinesia induced by risperidone? Am J Psychiatry 1996;153:843.
119. Gwinn KA, Caviness JN. Risperidone-induced tardive dyskinesia and parkinsonism. Mov Disord 1997;12:119-21.
120. Buzan RD. Risperidone-induced tardive dyskinesia. Am J Psychiatry 1996;153:734-5.
121. Silberbauer C. Risperidone-induced tardive dyskinesia. Pharmacopsychiatry 1998;31:68-9.
122. Daniel DG, Smith K, Hyde T, Egan M. Neuroleptic-induced tardive dyskinesia. Am J Psychiatry 1996;153:734.
123. Lykouras L, Yannakis R, Hatzimanolis J, Christodoulou GN. Two cases of risperidone-induced tardive dyskinesia and a review of the literature. Eur Psychiatry 1999;14:245-7.
124. Friedman JH. Rapid onset tardive dyskinesia ("fly catcher tongue") in a neuroleptically naive patient induced by risperidone. Med Health R I 1998;81:271-2.
125. Fischer P, Tauscher J, Kufferle B. Risperidone and tardive dyskinesia in organic psychosis. Pharmacopsychiatry 1998;31:70-1.
126. Ipekci S, Birsoz S. Tardive dyskinesia caused by the atypical antipsychotic risperidone and cured by the use of another drug of the same class, olanzapine. Eur Psychiatry 2001;16:259-60.
127. Mullen A. Risperidone and tardive dyskinesia: a case of blepharospasm. Aust N Z J Psychiatry 2000;34:879-80.
128. Chen JY, Bai YM, Pyng LY, Lin CC. Risperidone for tardive dyskinesia. Am J Psychiatry 2001;158:1931-2.
129. Kopala LC, Honer WG. Schizophrenia and severe tardive dyskinesia responsive to risperidone. J Clin Psychopharmacol 1994;14:430-1.
130. Chong SA, Remington G, Tan CH. Risperidone treatment of tardive dyskinesia and dystonia. J Clin Psychiatry 1999;60:340-1.
131. Kooptiwoot S, Settachan T. Improvement of tardive dyskinesia with risperidone: a case report. J Med Assoc Thai 2000;83:1430-2.
132. Soutullo CA, Keck PE, Jr., McElroy SL. Olanzapine in the treatment of tardive dyskinesia: a report of two cases. J Clin Psychopharmacol 1999;19:100-1.
133. Lykouras L, Malliori M, Christodoulou GN. Improvement of tardive dyskinesia following treatment with olanzapine. Eur Neuropsychopharmacol 1999;9:367-8.
134. Littrell KH, Johnson CG, Littrell S, Peabody CD. Marked reduction of tardive dyskinesia with olanzapine. Arch Gen Psychiatry 1998;55:279-80.
135. Almeida OP. Olanzapine for the treatment of tardive dyskinesia. J Clin Psychiatry 1998;59:380-1.
136. O'Brien J, Barber R. Marked improvement in tardive dyskinesia following treatment with olanzapine in an elderly subject. Br J Psychiatry 1998;172:186.
137. Durst R, Katz G, Zislin J, Raskin S, Kalman I. Rabbit syndrome treated with olanzapine. Br J Psychiatry 2000;176:193.
138. Khan M, Farver D. Rapid resolution of antipsychotic-induced tardive dyskinesia with olanzapine. S D J Med 2000;53:65-7.
139. Agarwal V, Kumar P. Olanzapine in the treatment of tardive dyskinesia: a report of 2 cases. J Clin Psychiatry 2001;62:298-9